DNA Financials | Key Metrics & Investor Analysis
The financial statements for DNA (DNA) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| MBX MBX Biosciences, Inc. Common Stock | $32.96 +0.46% |
| D Dominion Energy, Inc. | $62.38 -2.09% |
| REPL Replimune Group, Inc. | $2.28 +16.92% |
| MGTX MeiraGTx Holdings plc | $11.25 -0.35% |
| VALN Valneva SE | $6.03 -0.99% |
| AVBP ArriVent BioPharma, Inc. Common Stock | $29.41 +6.40% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences, Inc. Common Stock | $32.96 | +0.46% | 1.11 B | -13.85 | -2.38 | 0.00% | Buy | 307 |
| D Dominion Energy, Inc. | $62.38 | -2.09% | 54.83 B | 17.98 | 3.47 | 2.14% | Hold | 4.64 |
| REPL Replimune Group, Inc. | $2.28 | +16.92% | 188.27 M | -0.66 | -3.44 | 0.00% | Buy | 12.7 |
| MGTX MeiraGTx Holdings plc | $11.25 | -0.35% | 916.27 M | -7.92 | -1.42 | 0.00% | Buy | 643 |
| VALN Valneva SE | $6.03 | -0.99% | 518.85 M | -3.79 | -1.59 | 0.00% | Buy | 86 |
| AVBP ArriVent BioPharma, Inc. Common Stock | $29.41 | +6.40% | 1.30 B | -6.81 | -4.32 | 0.00% | Buy | 589 |
Frequently Asked Questions
What are DNA's latest financial results?
Review DNA's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has DNA's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is DNA's cash flow situation and liquidity?
Cash flow statements reveal how DNA generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does DNA's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether DNA is outperforming or lagging within its sector.
Are DNA's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether DNA's profits are repeatable and supported by strong fundamentals.